Abemaciclib Patents

Given below is the list of patents protecting Abemaciclib, along with the drug name that holds that patent and the company name owning that drug.

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Abemaciclib's patents.

Latest Legal Activities on Abemaciclib's Patents

Given below is the list recent legal activities going on the following patents of Abemaciclib.

Activity	Date	Patent Number
Critical Events for all Patents
Notice of Final Determination -Eligible	15 Dec, 2023	US7855211
FDA Final Eligibility Letter Critical	14 Nov, 2023	US7855211
transaction for FDA Determination of Regulatory Review Period	01 Mar, 2023	US7855211
transaction for FDA Determination of Regulatory Review Period	18 Jan, 2023	US7855211
Payment of Maintenance Fee, 12th Year, Large Entity	19 May, 2022	US7855211
Second letter to regulating agency to determine regulatory review period	26 Mar, 2021	US7855211
Electronic Review Critical	26 Jun, 2020	US7855211
Email Notification Critical	24 Jun, 2020	US7855211
Mail Certificate of Correction Memo	23 Jun, 2020	US7855211
Post Issue Communication - Certificate of Correction	19 Jun, 2020	US7855211

Abemaciclib's Family Patents

Full family tree

Explore Our Curated Drug Screens